New gout fighter challenges standard treatment in major trial
NCT ID NCT07414394
Summary
This study aims to see if a new drug called Tigulixostat works as well or better than the standard drug Febuxostat at lowering uric acid levels in people with gout. About 600 Chinese adults with gout will take one of these drugs for 52 weeks while researchers track their uric acid levels, gout flare-ups, safety, and overall health. The main goal is to see how many people can get their uric acid below a healthy target after 24 weeks of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GOUT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Fudan University HuaShan Hospital
RECRUITINGShanghai, Shanghai Municipality, 200040, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.